Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Dec 1;8(12):1775-83.
doi: 10.4161/hv.21739. Epub 2012 Sep 19.

Production of EV71 vaccine candidates

Pele Chong  1 , Shih-Yang Hsieh, Chia-Chyi Liu, Ai-Hsiang Chou, Jui-Yuan Chang, Suh-Chin Wu, Shih-Jen Liu, Yen-Hung Chow, Ih-Jen Su, Michel Klein
Affiliations
Review

Production of EV71 vaccine candidates

Pele Chong et al. Hum Vaccin Immunother. .

Abstract

Enterovirus 71 (EV71) is now recognized as an emerging neurotropic virus in Asia and with Coxsackie virus (CV) it is the other major causative agent of hand-foot-mouth diseases (HFMD). Effective medications and/or prophylactic vaccines against HFMD are urgently needed. From a scientific (the feasibility of bioprocess, immunological responses and potency in animal challenge model) and business development (cost of goods) points of view, we in this review address and discuss the pros and cons of different EV71 vaccine candidates that have been produced and evaluated in animal models. Epitope-based synthetic peptide vaccine candidates containing residues 211-225 of VP1 formulated with Freund's adjuvant (CFA/IFA) elicited low EV71 virus neutralizing antibody responses, but were protective in the suckling mouse challenge model. Among recombinant EV71 subunits (rVP1, rVP2 and rVP3) expressed in E. coli, purified and formulated with CFA/IFA, only VP1 elicited mouse antibody responses with measurable EV71-specific virus neutralization titers. Immunization of mice with either a DNA plasmid containing VP1 gene or VP1 expressed in Salmonella typhimurium also generated neutralizing antibody responses and protected animals against a live EV71 challenge. Recombinant EV71 virus-like particles (rVLP) produced from baculovirus formulated either with CFA/IFA or alum elicited good virus neutralization titers in both mice and non-human primates, and were found to be protective in the suckling mouse EV71 challenge model. Synthetic peptides or recombinant EV71 subunit vaccines (rVP1 and rVLP) formulated in alum were found to be poorly immunogenic in rabbits. Only formalin-inactivated (FI) EV71 virions formulated in alum elicited cross-neutralizing antibodies against different EV71 genotypes in mice, rabbits and non-human primates but induced weak neutralizing responses against CAV16. From a regulatory, economic and market acceptability standpoint, FI-EV71 virion vaccines are the most promising candidates and are currently being evaluated in human clinical trials. We further describe and analyze some new bioprocesses technologies that have great potential applications in EV71 vaccine development. This review also demonstrates the opportunities and challenges that the Asian vaccine industry faces today.

Trial registration: ClinicalTrials.gov NCT01507857 NCT01588247.

Keywords: enterovirus 71; formalin-inactivated whole virion vaccine; hand-foot-mouth diseases; synthetic peptide; virus neutralization titer; virus-like particle.

PubMed Disclaimer

References

    1. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. Taiwan Enterovirus Epidemic Working Group An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med. 1999;341:929–35. doi: 10.1056/NEJM199909233411301. - DOI - PubMed
    1. McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26:91–107. doi: 10.1111/j.1574-6976.2002.tb00601.x. - DOI - PubMed
    1. Xu J, Qian Y, Wang S, Serrano JMG, Li W, Huang Z, et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine. 2010;28:3516–21. doi: 10.1016/j.vaccine.2010.03.003. - DOI - PubMed
    1. Lee MS, Chang LY. Development of enterovirus 71 vaccines. Expert Rev Vaccines. 2010;9:149–56. doi: 10.1586/erv.09.152. - DOI - PubMed
    1. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778–90. doi: 10.1016/S1473-3099(10)70194-8. - DOI - PubMed

Publication types

MeSH terms

Associated data